Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Ellsworth Advisors LLC

Ellsworth Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,512 shares of the biopharmaceutical company’s stock after buying an additional 1,170 shares during the period. Ellsworth Advisors LLC’s holdings in Gilead Sciences were worth $933,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. Altfest L J & Co. Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $210,000. Abundance Wealth Counselors acquired a new stake in shares of Gilead Sciences during the third quarter worth about $1,881,000. Toronto Dominion Bank increased its position in shares of Gilead Sciences by 66.6% during the third quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock worth $96,589,000 after purchasing an additional 515,191 shares in the last quarter. Itau Unibanco Holding S.A. increased its position in shares of Gilead Sciences by 50.6% during the second quarter. Itau Unibanco Holding S.A. now owns 3,713 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 1,247 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. increased its position in shares of Gilead Sciences by 11.7% during the third quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the biopharmaceutical company’s stock worth $3,147,000 after purchasing an additional 4,400 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded up $0.24 during trading on Friday, hitting $73.25. 8,369,703 shares of the stock were exchanged, compared to its average volume of 7,477,960. The company has a fifty day moving average price of $75.11 and a two-hundred day moving average price of $77.29. The company has a market cap of $91.20 billion, a PE ratio of 16.28, a P/E/G ratio of 0.92 and a beta of 0.18. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12-month low of $71.37 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. Gilead Sciences’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $1.67 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.07 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.20%. Gilead Sciences’s payout ratio is 68.44%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GILD shares. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Oppenheimer lowered their price target on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. Barclays lowered their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Finally, Wells Fargo & Company lowered their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $85.36.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the transaction, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the transaction, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 8,242 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the transaction, the insider now owns 82,729 shares of the company’s stock, valued at $7,050,992.67. The disclosure for this sale can be found here. Insiders sold 15,242 shares of company stock worth $1,277,726 in the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.